Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | RGEN Repligen Corporation | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $180.71 +1.4% | $15.86 +3.2% |
| StockIQ Score | 66B- Moderate Risk: Medium | 38F Weak Risk: Medium |
| Technical | 86A | 21F |
| Fundamental | 58C | 35F |
| Growth | 65B- | 50C- |
| Fair Value | 50C- | 38F |
| News | 80A- | 50C- |
| Quality | 47D+ | 50C- |
| Risk | 54C- | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Repligen (RGEN) outperforms Ascentage Pharma (AAPG) across most categories. Its investor score (59 vs. 37) and growth score (65 vs. 50) are notably stronger, while its fundamental score (58 vs. 35) also leads. AAPG’s technical score (18) is far weaker, and both valuation scores are close (50 vs. 38), though RGEN’s overall rating is "Moderate" versus AAPG’s "Weak."
